NO20083670L - Forbindelser og fremgangsmater for modulering av proteinomsetning - Google Patents
Forbindelser og fremgangsmater for modulering av proteinomsetningInfo
- Publication number
- NO20083670L NO20083670L NO20083670A NO20083670A NO20083670L NO 20083670 L NO20083670 L NO 20083670L NO 20083670 A NO20083670 A NO 20083670A NO 20083670 A NO20083670 A NO 20083670A NO 20083670 L NO20083670 L NO 20083670L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- compounds
- modulating protein
- protein conversion
- protein turnover
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
Abstract
Offentliggjort er sammensetninger og metoder for å modulere proteinomsetning og å behandle eller forhindre sykdommer karakterisert ved svekket proteinomsetning. Også offentliggjort er metoder for identifisering av forbindelser som berger protein omsetningsdefekter og metoder for å forsterke proteinproduksjon.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76295506P | 2006-01-26 | 2006-01-26 | |
US85794006P | 2006-11-09 | 2006-11-09 | |
PCT/US2007/002102 WO2007089548A2 (en) | 2006-01-26 | 2007-01-26 | Compounds and methods for modulating protein trafficking |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083670L true NO20083670L (no) | 2008-10-27 |
Family
ID=38327890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083670A NO20083670L (no) | 2006-01-26 | 2008-08-26 | Forbindelser og fremgangsmater for modulering av proteinomsetning |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100004277A1 (no) |
EP (1) | EP1976839A4 (no) |
JP (1) | JP2009525966A (no) |
AU (1) | AU2007210159A1 (no) |
CA (1) | CA2640454A1 (no) |
NO (1) | NO20083670L (no) |
NZ (1) | NZ570103A (no) |
WO (1) | WO2007089548A2 (no) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005287137B2 (en) * | 2004-09-17 | 2012-03-22 | Foldrx Pharmaceuticals, Inc. | Compounds, compositions and methods of inhibiting a-synuclein toxicity |
CA3004867C (en) | 2008-06-26 | 2020-09-15 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
EP2391604A1 (en) * | 2008-12-23 | 2011-12-07 | F. Hoffmann-La Roche AG | Dihydropyridone amides as p2x7 modulators |
CN101760557B (zh) * | 2010-03-04 | 2013-08-14 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种辅助诊断肝细胞癌的试剂盒 |
DK2592934T3 (en) | 2010-07-16 | 2015-10-26 | Nivalis Therapeutics Inc | NOVEL dihydropyridin-2 (1H) -one compounds as S-NITROSOGLUTATHIONREDUKTASEINHIBITORER and neurokinin-3 receptor antagonists |
US20130158035A1 (en) * | 2010-08-24 | 2013-06-20 | Brigham Young University | Antimetastatic compounds |
US20130196990A1 (en) | 2010-10-06 | 2013-08-01 | Junya Qu | Benzimidazole Derivatives As PI3 Kinase Inhibitors |
US9802948B2 (en) | 2010-10-13 | 2017-10-31 | Trustees Of Boston Univeristy | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics |
CN103347520A (zh) | 2010-10-13 | 2013-10-09 | 波士顿大学管理委员会 | 用作癌症化学治疗的晚期sv40因子(lsf)的抑制剂 |
US9815845B2 (en) | 2010-10-13 | 2017-11-14 | Trustees Of Boston University | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics |
US9116157B2 (en) | 2010-11-05 | 2015-08-25 | Brandeis University | Ice-cleaved alpha-synuclein as a biomarker |
WO2012072082A1 (en) | 2010-11-30 | 2012-06-07 | Orphazyme Aps | Methods for increasing intracellular activity of hsp70 |
WO2013111118A2 (en) * | 2012-01-26 | 2013-08-01 | Cro Consulting Limited | Agents for treating neurodegenerative disorders |
EP3174872A1 (en) * | 2014-07-29 | 2017-06-07 | Université de Lille 2 Droit et Santé | 2-oxo-3,4-dihydropyridine-5-carboxylates and their use |
PL3193840T3 (pl) | 2014-09-15 | 2021-12-06 | Orphazyme A/S | Preparat arimoklomolu |
WO2017178029A1 (en) | 2016-04-13 | 2017-10-19 | Orphazyme Aps | Heat shock proteins and cholesterol homeostasis |
PT3448382T (pt) | 2016-04-29 | 2020-11-20 | Orphazyme As C/O Cobis As | Arimoclomol para o tratamento de distúrbios associados à glucocerebrosidase |
WO2020028757A1 (en) | 2018-08-02 | 2020-02-06 | Trustees Of Boston University | Late sv40 factor (lsf) inhibitors |
WO2021150835A1 (en) | 2020-01-24 | 2021-07-29 | Trustees Of Boston University | Heterocyclic lsf inhibitors and their uses |
US11458132B2 (en) | 2020-09-01 | 2022-10-04 | Trustees Of Boston University | Quinolin-2(1H)-one inhibitors of Late SV40 Factor |
MX2023005954A (es) | 2020-11-19 | 2023-09-04 | Zevra Denmark As | Procesos para preparar citrato de arimoclomol e intermediarios del mismo. |
CN115406885B (zh) * | 2022-11-01 | 2023-02-03 | 常州百瑞吉生物医药有限公司 | 一种二硫键交联透明质酸凝胶中交联剂残留的检测方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5516149B2 (no) * | 1972-01-14 | 1980-04-30 | ||
EP3222619A1 (en) * | 1999-04-15 | 2017-09-27 | Bristol-Myers Squibb Holdings Ireland | Cyclic protein tyrosine kinase inhibitors |
US6916813B2 (en) * | 2001-12-10 | 2005-07-12 | Bristol-Myers Squibb Co. | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
WO2005026137A2 (en) * | 2003-09-06 | 2005-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
EA012328B1 (ru) * | 2004-01-12 | 2009-08-28 | Лаборатуар Сероно Са | Производные тиазола и их применение |
EP3219709B1 (en) * | 2004-01-30 | 2020-03-18 | Vertex Pharmaceuticals Incorporated | Intermediate compound of modulators of atp-binding cassette transporters |
AR049333A1 (es) * | 2004-04-02 | 2006-07-19 | Vertex Pharma | Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas. |
AU2005287137B2 (en) * | 2004-09-17 | 2012-03-22 | Foldrx Pharmaceuticals, Inc. | Compounds, compositions and methods of inhibiting a-synuclein toxicity |
-
2007
- 2007-01-26 WO PCT/US2007/002102 patent/WO2007089548A2/en active Application Filing
- 2007-01-26 NZ NZ570103A patent/NZ570103A/en not_active IP Right Cessation
- 2007-01-26 US US12/162,143 patent/US20100004277A1/en not_active Abandoned
- 2007-01-26 AU AU2007210159A patent/AU2007210159A1/en not_active Abandoned
- 2007-01-26 CA CA002640454A patent/CA2640454A1/en not_active Abandoned
- 2007-01-26 EP EP07717027A patent/EP1976839A4/en not_active Withdrawn
- 2007-01-26 JP JP2008552417A patent/JP2009525966A/ja active Pending
-
2008
- 2008-08-26 NO NO20083670A patent/NO20083670L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2007210159A1 (en) | 2007-08-09 |
NZ570103A (en) | 2011-11-25 |
EP1976839A4 (en) | 2011-06-15 |
EP1976839A2 (en) | 2008-10-08 |
CA2640454A1 (en) | 2007-08-09 |
JP2009525966A (ja) | 2009-07-16 |
US20100004277A1 (en) | 2010-01-07 |
WO2007089548A2 (en) | 2007-08-09 |
WO2007089548A3 (en) | 2008-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083670L (no) | Forbindelser og fremgangsmater for modulering av proteinomsetning | |
NO20076401L (no) | Diarylhydantoinforbindelser | |
DK1592786T3 (da) | Diagnosticering og behandling af multipel sulfatase-defekt og andet ved anvendelse af et formylglycin-dannende enzym (FGE). | |
NO20081042L (no) | PPAR aktive forbindelser | |
WO2010031056A3 (en) | Methods and compositions for modulating ire1, src, and abl activity | |
DK1836169T3 (da) | Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser | |
NO20045429L (no) | Kombinasjon av organiske forbindelser | |
NO20075304L (no) | Metode for avtagende forkalkning | |
DK1877390T3 (da) | Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf | |
EA201270553A1 (ru) | Ингибиторы тирозинкиназы брутона | |
NO20081454L (no) | Met-kinaseinhibitorer | |
NO20075471L (no) | Betjening av en eller flere drivstoffautomater | |
NO20084374L (no) | Imidazoltiazolforbindelser for behandling av sykdom | |
EA200700851A1 (ru) | Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения | |
TW200738753A (en) | Methods for modulating mannose content of recombinant proteins | |
NO20091926L (no) | Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer | |
ATE497492T1 (de) | Reinigung von montelukast | |
DE602006015215D1 (de) | Prolinamidderivate als natriumkanalmodulatoren | |
ATE435209T1 (de) | Verfahren zur herstellung von montelukast-natrium | |
EA201070127A1 (ru) | Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления | |
NO20090969L (no) | Sammensetninger og fremgangsmater som anvender anti-CS1 antistoffer for a behandle multippel myeloma | |
ATE504836T1 (de) | Verfahren zur identifizierung von trpv2- modulatoren | |
EA201170590A1 (ru) | Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения | |
EA200800889A1 (ru) | Гексагидроциклооктилпиразольные каннабиноидные модуляторы | |
NO20080462L (no) | Krystallformer av astaxantin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |